Safety of beta-blockers in COPD: The jury must still be out [4]

QJM: An International Journal of Medicine

Volumn 98, Issue 9, 2005, Pages 706-707

  Lee, D K C ^a   Borade, P S ^a   Currie, G P ^b  

^a IPSWICH HOSPITAL   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; METOPROLOL; PROPRANOLOL;

ASTHMA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DESENSITIZATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG USE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; LETTER; LUNG DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 24144448041     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hci106     Document Type: Letter

References (3)

1. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. Q J Med 2005; 98 493-7.
2. The British Thoracic Society and Scottish Intercollegiate Guidelines Network 2004 update to the British guideline on the management of asthma. [http://www.brit-thoracic.org.uk/docs/asthmafull.pdf]
3. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: A concern for nonselective beta-blockers. Chest 2005; 127:818-24.